PFE · News · 20261112N
GLP-1 Development Funding Deal
PFIZER INC · 2026-11-12 · Importance 53 · Surprise 42 · In source text
Blackstone Life Sciences will provide Pfizer up to $1.5 billion through 2028 to fund development of berobenatide, an investigational monthly GLP-1 receptor agonist for chronic weight management. Pfizer will retain full ownership, operational control, and decision-making authority over the drug. Blackstone may receive milestone-based payments tied to U.S. regulatory approval and commercial sales, payable over multiple years if earned. Berobenatide is in Phase III trials for obesity and related comorbidities.
Key facts
- Pfizer entered a co-funding agreement with Blackstone Life Sciences for development of berobenatide, its investigational monthly GLP-1 receptor agonist. source
- Pfizer plans to conduct over 20 trials of berobenatide, including Phase 3 studies. source
- If earned, the milestone payments to Blackstone will be made over multiple years. source
- Blackstone will not acquire rights or ownership in berobenatide; Pfizer will retain full operational control and decision-making authority for the program. source
- Berobenatide Phase 2b data showed average non-placebo-adjusted weight loss of 15.9%. source
- Berobenatide is currently in Phase III trials for obesity and related comorbidities. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | committed | — | Pfizer entered a co-funding agreement with Blackstone Life Sciences for development of berobenatide, its investigational monthly GLP-1… |
| operating_income | negative | probable | — | Pfizer plans to conduct over 20 trials of berobenatide, including Phase 3 studies. |
| cash | negative | contingent | — | If earned, the milestone payments to Blackstone will be made over multiple years. |